PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för ixabepilone. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

15 hits

Bibliografisk träff 2011-11-22

RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer.

Vishnu P, Colon-Otero G, Kennedy GT, Marlow LA, Kennedy WP, Wu KJ, Santoso JT, Copland JA.

Gynecol Oncol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.ygyno.2011.11.019

Bibliografisk träff 2011-11-20

The paradox of triple negative breast cancer: novel approaches to treatment.

Fornier M, Fumoleau P.

Breast J · research support, non-u.s. gov't; review; journal article · DOI 10.1111/j.1524-4741.2011.01175.x

Bibliografisk träff 2011-09-21

Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies.

Jassem J, Fein L, Karwal M, Campone M, Peck R, Poulart V, Vahdat L.

Breast · clinical trial, phase iii; research support, non-u.s. gov't; journal article · DOI 10.1016/j.breast.2011.09.003

Bibliografisk träff 2011-05-19

Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer.

Corey-Lisle PK, Peck R, Mukhopadhyay P, Orsini L, Safikhani S, Bell JA, Hortobagyi G, Roche H, Conte P, Revicki DA.

Cancer · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1002/cncr.26213

Bibliografisk träff 2011-05-19

Epothilones in development for non--small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance.

Edelman MJ, Shvartsbeyn M.

Clin Lung Cancer · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.cllc.2011.02.005

Bibliografisk träff 2011-05-17

Ixabepilone for the treatment of breast cancer.

Alvarez RH, Valero V, Hortobagyi GN.

Ann Med · research support, non-u.s. gov't; review; journal article · DOI 10.3109/07853890.2011.579151

Bibliografisk träff 2011-05-01

Global experience with ixabepilone in breast cancer.

Kaklamani VG, Xu BH, Gomez HL.

Expert Rev Anticancer Ther · review; journal article · DOI 10.1586/era.11.41

Bibliografisk träff 2011-04-20

Ixabepilone: clinical role in metastatic breast cancer.

Denduluri N, Swain S.

Clin Breast Cancer · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.clbc.2011.03.009

Bibliografisk träff 2011-04-01

Epothilones in the treatment of ovarian cancer.

Diaz-Padilla I, Oza AM.

Future Oncol · research support, non-u.s. gov't; review; journal article · DOI 10.2217/fon.11.26

Bibliografisk träff 2011-01-24

Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).

Shen H, Lee FY, Gan J.

J Pharmacol Exp Ther · research support, non-u.s. gov't; journal article · DOI 10.1124/jpet.110.175604

Bibliografisk träff 2011-01-13

Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer.

Rak Tkaczuk KH.

Breast Cancer (Auckl) · review-article; journal article · DOI 10.4137/bcbcr.s5331

Bibliografisk träff 2011-01-01

Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence.

Lee F, Jure-Kunkel MN, Salvati ME.

Ther Adv Med Oncol · review-article; journal article · DOI 10.1177/1758834010386402

Bibliografisk träff 2010-12-03

Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies.

Roché H, Conte P, Perez EA, Sparano JA, Xu B, Jassem J, Peck R, Kelleher T, Hortobagyi GN.

Breast Cancer Res Treat · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1007/s10549-010-1251-y

Bibliografisk träff 2010-10-27

Weekly ixabepilone administration in heavily pretreated metastatic breast cancer patients.

Kossoff EB, Ngamphaiboon N, Laudico TJ, O'Connor TL.

Med Oncol · journal article · DOI 10.1007/s12032-010-9726-6

Bibliografisk träff 2010-03-09

Alternative dosing schedules and administration updates for ixabepilone.

Kossoff E.

J Oncol Pharm Pract · review; journal article · DOI 10.1177/1078155210364273